Opportunity for M.Pharm, MSc to Join PGIMER as Trial Co-ordinator
A Phase-lV, single-arm, multicentric study to assess the safety of SIIPLs qHPV vaccineCERVAVAC when administered in a two-dose schedule to girls and boys aged 9-14 years and in a three dose schedule to women and men aged 15-26